Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Genetics

How Is Enzyme Replacement Therapy Administered for Fabry?

At a Glance

Enzyme Replacement Therapy (ERT) for Fabry disease is administered via an intravenous (IV) infusion every two weeks. Treatment is lifelong, takes 40 to 90 minutes per session, and can often be safely transitioned to convenient home infusions once a patient is stable.

Enzyme Replacement Therapy (ERT) for Fabry disease is administered via an intravenous (IV) infusion typically every two weeks [1][2]. Because the body cannot naturally produce the necessary enzyme (alpha-galactosidase A), this treatment is a lifelong commitment. Infusions can take anywhere from about an hour to a few hours, and while many patients start their treatment journey in a medical clinic, those who are physically stable often transition to the convenience of home infusions [1][3].

How the Infusion Works

  • Route and Frequency: The replacement enzyme is delivered directly into your bloodstream through an IV. Standard treatment schedules require an infusion every two weeks to maintain adequate enzyme levels in your body [1][4]. Note: The specific enzyme formulations available vary by region. For example, agalsidase alfa is used globally but is not currently FDA-approved in the United States, where agalsidase beta and other options are standard [5][6].
  • Duration of Appointments: The length of your infusion depends on the specific medication you are taking and how your body reacts. Some enzyme formulations typically take 40 to 60 minutes. Others traditionally take longer, but if you are a stable adult patient who has not had recent allergic reactions, the infusion time can sometimes be safely shortened to 90 minutes [7].
  • Lifelong Treatment and Symptom Relief: ERT replaces the enzyme your body cannot make on its own. Because it is a replacement rather than a permanent fix, the therapy must be continued for life. Consistent ERT not only helps protect your major organs by slowing the decline of kidney and heart function [2][5], but it has also been shown to significantly alleviate daily symptoms, such as burning neuropathic pain (acroparesthesia) and severe gastrointestinal distress [8][9].

Getting the IV and Venous Access

Since ERT is a lifelong therapy requiring an IV every two weeks, it can sometimes become difficult to find a healthy vein in your arm. If you have “hard to find” veins or want to avoid being poked with a needle every two weeks, your doctor may discuss placing a long-term central venous access device, such as a port-a-cath [10][3]. A port-a-cath is a small medical device implanted under the skin that allows the nurse easy, reliable access to deliver the IV medication without repeatedly searching for a vein.

Where Infusions Take Place

  • Clinic or Hospital: When you first start ERT, you will likely receive your infusions in a clinical setting, such as a hospital or a specialized infusion center. This allows your healthcare team to monitor you closely for any allergic or infusion-related reactions [7].
  • Home Infusions: Once you are on a stable dose and tolerate the treatment well, you may be eligible for home infusions. Studies show that home-based ERT programs are safe, feasible, and can significantly improve a patient’s day-to-day quality of life by returning time and freedom [3][11]. In home programs, a specialized nurse comes to your house to administer the IV. In some programs, patients and their caregivers might even be trained to safely self-administer the medication [12].

Managing Side Effects and Reactions

While ERT is generally well-tolerated, some people experience infusion-associated reactions (IRRs) such as chills, fever, or a skin rash [13]. To prevent these symptoms, your doctor might prescribe pre-medications for you to take shortly before your infusion begins. Common pre-medications include:

  • Antihistamines (like Benadryl) to prevent an allergic response.
  • Antipyretics (like acetaminophen) to prevent a fever.

If a reaction does occur during the treatment, the nurse can safely slow down the IV drip rate or temporarily pause the infusion altogether until you feel better [7][13].

Over time, your doctor will continuously monitor your heart, kidneys, and bloodwork. This includes checking for anti-drug antibodies—proteins your immune system might mistakenly create to fight the replacement enzyme, which can make the therapy less effective over time [14][15].

What If I Miss a Dose or Need an Alternative?

Because the enzyme must be consistently replenished, sticking to your biweekly schedule is critical; delayed initiation and interruptions in the schedule are linked to poorer long-term health outcomes [16][1]. If you plan to travel or become ill, coordinate with your care team in advance. Many patients utilize home infusion networks to maintain their schedule while traveling [3].

If ERT is poorly tolerated or if you develop antibodies that block the enzyme, you are not out of options. Depending on your specific genetic mutation, your doctor may consider switching formulations or prescribing an alternative treatment, such as an oral pharmacological chaperone therapy (e.g., migalastat), which comes in pill form [17][10].

Common questions in this guide

How often do I need to get Enzyme Replacement Therapy for Fabry disease?
Enzyme Replacement Therapy (ERT) is typically administered every two weeks through an intravenous (IV) infusion. This consistent schedule is necessary to maintain adequate enzyme levels in your body.
Can I receive my Fabry disease ERT infusions at home?
Yes, once you are on a stable dose and tolerate the treatment well, you may be eligible for home infusions. A specialized nurse can come to your house to administer the IV, or you and your caregiver may be trained to do it safely.
What should I do if my veins are hard to find for my biweekly IVs?
If finding a vein becomes difficult or painful, your doctor may recommend placing a long-term central venous access device, such as a port-a-cath. This small device sits under your skin and provides reliable IV access for your nurse.
How do doctors manage side effects or reactions during an ERT infusion?
If you experience infusion-related reactions like chills or fever, your doctor can prescribe pre-medications such as antihistamines or acetaminophen. During an infusion, the nurse can also slow down the IV drip rate or temporarily pause it until your symptoms improve.
What happens if I miss an ERT dose or need an alternative treatment?
Sticking to your biweekly schedule is critical, so you should coordinate with your care team before traveling. If you cannot tolerate ERT or develop antibodies, your doctor might switch your formulation or prescribe an oral chaperone therapy pill, depending on your genetic mutation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for home infusions down the line, and what specific clinical milestones do I need to reach to be approved for them?
  2. 2.What specific pre-medications do you recommend I take before my infusions to minimize the risk of a reaction?
  3. 3.If I have difficult veins and biweekly needle pokes become too painful, at what point should we discuss a long-term access device like a port-a-cath?
  4. 4.What is our specific protocol if I get sick, go on vacation, or otherwise need to delay my scheduled infusion date?
  5. 5.How frequently will you monitor my bloodwork for anti-drug antibodies, and what are our alternative options if they develop?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.

    Sasa H, Nagao M, Kino K

    Molecular genetics and metabolism 2019; (126(4)):448-459 doi:10.1016/j.ymgme.2019.02.005.

    PMID: 30803893
  2. 2

    Successful Management of Pregnancy in a Patient With Fabry Disease Receiving Continuous Enzyme Replacement Therapy: A Case Report and Literature Review.

    Kido Y, Nakahara M, Takahashi K, et al.

    Cureus 2025; (17(5)):e83342 doi:10.7759/cureus.83342.

    PMID: 40458361
  3. 3

    Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond.

    Nowicki M, Bazan-Socha S, Kłopotowski M, et al.

    International journal of environmental research and public health 2021; (18(16)) doi:10.3390/ijerph18168242.

    PMID: 34443990
  4. 4

    Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol.

    Riccio E, Zanfardino M, Franzese M, et al.

    Molecular genetics & genomic medicine 2021; (9(5)):e1659 doi:10.1002/mgg3.1659.

    PMID: 33755336
  5. 5

    Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.

    Ramaswami U, Pintos-Morell G, Kampmann C, et al.

    Molecular genetics and metabolism reports 2025; (43()):101215 doi:10.1016/j.ymgmr.2025.101215.

    PMID: 40276560
  6. 6

    Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data.

    Feriozzi S, Chimenti C, Reisin RC

    Drug design, development and therapy 2024; (18()):1083-1101 doi:10.2147/DDDT.S365885.

    PMID: 38585254
  7. 7

    Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease.

    Germain DP, Porto Vasconcelos A, Tran Thi Phuong L, et al.

    Biomedicines 2024; (12(11)) doi:10.3390/biomedicines12112578.

    PMID: 39595144
  8. 8

    Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.

    Mignani R, Biagini E, Cianci V, et al.

    Advances in therapy 2025; (42(2)):597-635 doi:10.1007/s12325-024-03041-2.

    PMID: 39636569
  9. 9

    Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype.

    Hopkin RJ, Feldt-Rasmussen U, Germain DP, et al.

    Molecular genetics and metabolism reports 2020; (25()):100670 doi:10.1016/j.ymgmr.2020.100670.

    PMID: 33163363
  10. 10

    Treatment of Anderson-Fabry Disease.

    Simonetta I, Tuttolomondo A, Daidone M, et al.

    Current pharmaceutical design 2020; (26(40)):5089-5099 doi:10.2174/1381612826666200317142412.

    PMID: 32183665
  11. 11

    Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued.

    Politei J

    Molecular genetics and metabolism 2020; (130(4)):227-229 doi:10.1016/j.ymgme.2020.06.002.

    PMID: 32561366
  12. 12

    Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys.

    Revel-Vilk S, Ramaswami U, Pintos-Morell G, et al.

    Orphanet journal of rare diseases 2025; (20(1)):145 doi:10.1186/s13023-024-03416-2.

    PMID: 40155993
  13. 13

    Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.

    Tsuboi K, Yamamoto H

    BMC pharmacology & toxicology 2017; (18(1)):43 doi:10.1186/s40360-017-0152-7.

    PMID: 28592315
  14. 14

    Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

    Lenders M, Oder D, Nowak A, et al.

    Journal of internal medicine 2017; (282(3)):241-253 doi:10.1111/joim.12647.

    PMID: 28682471
  15. 15

    Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis.

    Riccio E, Capuano I, Buonanno P, et al.

    Clinical kidney journal 2025; (18(11)):sfaf318 doi:10.1093/ckj/sfaf318.

    PMID: 41377851
  16. 16

    Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis.

    Hughes D, Linhart A, Gurevich A, et al.

    Drug design, development and therapy 2021; (15()):3561-3572 doi:10.2147/DDDT.S313789.

    PMID: 34429585
  17. 17

    Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease.

    Germain DP, Linhart A

    Frontiers in genetics 2024; (15()):1395287 doi:10.3389/fgene.2024.1395287.

    PMID: 38680424

This page explains Enzyme Replacement Therapy administration for Fabry disease for educational purposes only. Always consult your healthcare team for medical advice regarding your specific treatment plan and infusion schedule.

Get notified when new evidence is published on Fabry disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.